Aadi Bioscience (FRA:3350) Debt-to-EBITDA : -0.02 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Aadi Bioscience Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Aadi Bioscience's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.39 Mil. Aadi Bioscience's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.68 Mil. Aadi Bioscience's annualized EBITDA for the quarter that ended in Mar. 2024 was €-66.91 Mil. Aadi Bioscience's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.02.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Aadi Bioscience's Debt-to-EBITDA or its related term are showing as below:

FRA:3350' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.87 Med: -0.02 Max: -0.01
Current: -0.02

During the past 4 years, the highest Debt-to-EBITDA Ratio of Aadi Bioscience was -0.01. The lowest was -3.87. And the median was -0.02.

FRA:3350's Debt-to-EBITDA is ranked worse than
100% of 274 companies
in the Biotechnology industry
Industry Median: 1.31 vs FRA:3350: -0.02

Aadi Bioscience Debt-to-EBITDA Historical Data

The historical data trend for Aadi Bioscience's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aadi Bioscience Debt-to-EBITDA Chart

Aadi Bioscience Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

-3.87

-0.01

-0.03

-0.02

Aadi Bioscience Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-EBITDA	Get a 7-Day Free Trial										-0.03	-0.02	-0.02	-0.02	-0.02

Competitive Comparison of Aadi Bioscience's Debt-to-EBITDA

For the Biotechnology subindustry, Aadi Bioscience's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aadi Bioscience's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aadi Bioscience's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Aadi Bioscience's Debt-to-EBITDA falls into.

Aadi Bioscience Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Aadi Bioscience's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.398	+	0.764)	/	-59.94
	=	-0.02

Aadi Bioscience's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.391	+	0.679)	/	-66.908
	=	-0.02

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.

Aadi Bioscience (FRA:3350) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Aadi Bioscience Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Aadi Bioscience's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Aadi Bioscience (FRA:3350) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aadi Bioscience Inc (FRA:3350) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

AADI:USA 3350:Germany

Address

17383 Sunset Boulevard, Suite A250, Pacific Palisades, CA, USA, 90272

Website

https://www.aadibio.com

Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.

Aadi Bioscience (FRA:3350) Headlines

No Headlines